Scholar Rock, Inc.

Genetics Institute, Inc.

Other

Nucryst Pharmaceuticals Corp.

Katherine Jane Turner

Michelle Marie Straub

Steven C Clark

Rodney M Hewick

Thomas G Gesner

Kenneth A Jacobs

Nagesh K Mahanthappa

Gregory John Carven

Justin W Jackson

Dong Yun Lee

William K McConaughy

Adriana Donovan

Naoya Tsurushita

Clive R Wood

Mary Collins

Gary S Gray

Paul Robert Hinton

Thomas Schurpf

Beatriz M Carreno

Denise M O'Hara

Paul Schechter

Xiao-jia Chang

Ullrich S Schwertschlag

Donna Morris

Jeffrey B Lyczak

Katherine Thompson

ProTGFβ1-GARP complex-selective antibodies, polynucleotides capable of encoding the proTGFβ1-GARP complex-selective antibodies or antigen-binding fragments, cells expressing proTGFβ1-GARP complex-selective antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled proTGFβ1-GARP complex-selective antibodies or antigen-binding fragments may be used to enhance an immune response in a subject, for example, against a cancer.

TGFβ antibodies, methods and uses

Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.

Compositions for making and using anti-Myostatin antibodies

Methods for using anti-myostatin antibodies

Methods for making and using anti-myostatin antibodies

Anti-pro/latent-Myostatin antibodies and uses thereof

Anti-pro/latent-myostatin antibodies and uses thereof

Antibody molecules that specifically bind to one or more isoforms expressed and/or associated with oncogenic phenotypes in a hyperproliferative cell (e.g., a cancerous or tumor cell) are disclosed. The isoform-binding antibody molecules can be used to treat, prevent and/or diagnose cancerous conditions and/or disorders. Methods of using the isoform-binding molecules to selectively detect oncogenic isoforms, to reduce the activity and/or induce the killing of a hyperproliferative cell expressing an oncogenic isoform in vitro, ex vivo or in vivo are also disclosed. Diagnostic and/or screening methods and kits for evaluating the function or expression of an oncogenic isoform are also disclosed.

Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof

Metal-containing materials, as well as their preparation, formulations, and use are disclosed.

Metal-containing materials for treatment of bacterial conditions

Novel polypeptides of human megakaryocyte stimulating factors (MSFs). Pharmaceutical compositions containing same, and methods for their preparation and use are provided.

Megakaryocyte stimulating factors

The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The invention further provides anti-CTLA4 antibodies and humanized forms thereof.

Antibodies against CTLA4

Novel human megakaryocyte stimulating factors (MSFS) capable of stimulating the growth and development of colonies of megakaryocytes, pharmaceutical compositions containing same, and methods for their preparation and use are provided.

Angel in bowl figurine

A novel human megakaryocytopoietic factor capable of stimulating the growth and development of colonies of megakaryocytes is provided, including procedures for its purification and use as a pharmaceutical agent.

Megakaryocytopoietic factor

Growing community of inventors

Acton, MA, United States of America

Katherine Jane Turner